{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:25:50Z","timestamp":1791555950544,"version":"4.3.4"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3744,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>New-onset diabetes mellitus (NODM) develops in approximately 15% of liver transplant recipients, and a similar proportion of patients have diabetes prior to transplantation. Preexisting diabetes and probably NODM are associated with increased mortality and risk of infection. NODM occurs more frequently among patients with hepatitis C infection; additional risk factors include family history, male gender, increasing weight, and alcoholic cirrhosis. Corticosteroid therapy, particularly bolus injections, increases likelihood of NODM, and randomized clinical trials and retrospective studies have shown NODM to occur more frequently with tacrolimus compared with cyclosporine. Patients undergoing liver transplantation should be screened for diabetes risk factors, and fasting plasma glucose should be monitored regularly in all transplant recipients. Management of NODM is essentially similar to that of diabetes in the nontransplant population, and includes dietary and lifestyle modifications. In choosing oral agents and\/or insulin, the individual medical profile of the patient must be considered carefully. Corticosteroid exposure should be limited as much as possible, and reduction of calcineurin inhibitor dose is prudent. Switching from tacrolimus to cyclosporine may be required in some cases to achieve improvement or resolution. In conclusion, prospective trials are necessary to properly define antidiabetic therapy and immunosuppressive strategies in this population.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.20439","type":"journal-article","created":{"date-parts":[[2005,5,24]],"date-time":"2005-05-24T20:46:31Z","timestamp":1116967591000},"page":"612-620","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":98,"title":["New-Onset Diabetes After Liver Transplantation: From Pathogenesis to Management"],"prefix":"10.1097","volume":"11","author":[{"given":"Piero","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20250124","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis.","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant"},{"key":"R2-5-20250124","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0041-1345(03)00528-1","article-title":"Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding.","volume":"35","author":"Tueche","year":"2003","journal-title":"Transplant Proc"},{"key":"R3-5-20250124","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/jlts.2001.22183","article-title":"Liver transplantation in cirrhotic patients with diabetes mellitus: Midterm results, survival and adverse events.","volume":"7","author":"Blanco","year":"2001","journal-title":"Liver Transpl"},{"key":"R4-5-20250124","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/00007890-200210150-00019","article-title":"The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation.","volume":"74","author":"Yoo","year":"2002","journal-title":"Transplantation"},{"key":"R5-5-20250124","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/jhep.2001.29134","article-title":"Outcome of liver transplantation in patients with diabetes mellitus: A case-control study.","volume":"34","author":"John","year":"2001","journal-title":"Hepatology"},{"key":"R7-5-20250124","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection.","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R8-5-20250124","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1097\/00007890-199712270-00023","article-title":"Prednisone withdrawal 14 days after liver transplantation with mycophenolate: A prospective trial of cyclosporine and tacrolimus.","volume":"64","author":"Stegall","year":"1997","journal-title":"Transplantation"},{"issue":"Suppl","key":"R9-5-20250124","first-page":"S5","article-title":"Report of the Expert committee on the diagnosis and classification of diabetes mellitus.","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"R10-5-20250124","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/lt.500020405","article-title":"Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation.","volume":"2","author":"Trail","year":"1996","journal-title":"Liver Transpl Surg"},{"key":"R11-5-20250124","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/jlts.2002.34638","article-title":"Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus.","volume":"8","author":"John","year":"2002","journal-title":"Liver Transpl"},{"key":"R12-5-20250124","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/00007890-200109270-00015","article-title":"Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality.","volume":"72","author":"Baid","year":"2001","journal-title":"Transplantation"},{"key":"R13-5-20250124","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0168-8278(96)80329-1","article-title":"Diabetes mellitus after liver transplantation: Prevalence and predictive factors.","volume":"25","author":"Navasa","year":"1996","journal-title":"J Hepatol"},{"key":"R14-5-20250124","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-2000-8136","article-title":"Liver transplantation and diabetes mellitus.","volume":"108","author":"Steinmuller","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R15-5-20250124","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00007890-199409000-00006","article-title":"The effect of FK506 versus cyclosporine on glucose and lipid metabolisma randomized trial.","volume":"58","author":"Steinmuller","year":"1994","journal-title":"Transplantation"},{"key":"R16-5-20250124","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0041-1345(02)03027-0","article-title":"Posttransplant diabetes mellitus after orthotopic liver transplantation.","volume":"34","author":"Stockmann","year":"2002","journal-title":"Transplant Proc"},{"key":"R17-5-20250124","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1053\/jlts.2002.31745","article-title":"Postliver transplant diabetes mellitus: An association with hepatitis C.","volume":"8","author":"AlDosary","year":"2002","journal-title":"Liver Transplant"},{"key":"R18-5-20250124","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States.","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am J Transplant"},{"key":"R19-5-20250124","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00007890-199102000-00014","article-title":"Diabetes mellitus after renal transplantation in the cyclosporine eraan analysis of risk factors.","volume":"51","author":"Sumrani","year":"1991","journal-title":"Transplantation"},{"key":"R20-5-20250124","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/jhep.2000.8270","article-title":"Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation.","volume":"32","author":"Bigam","year":"2000","journal-title":"Hepatology"},{"key":"R21-5-20250124","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4065\/75.4.355","article-title":"Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection.","volume":"75","author":"Knobler","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"R22-5-20250124","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/01.TP.0000114283.04840.3A","article-title":"Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation.","volume":"77","author":"Delgado-Borrego","year":"2004","journal-title":"Transplantation"},{"key":"R24-5-20250124","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2337\/diacare.25.3.583","article-title":"Posttrasplantation diabetes: A systematic review of the literature.","volume":"25","author":"Montori","year":"2002","journal-title":"Diabetes Care"},{"key":"R25-5-20250124","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00002018-199615020-00005","article-title":"Drug-induced disorders of glucose metabolism. Mechanisms and management.","volume":"15","author":"Chan","year":"1996","journal-title":"Drug Saf"},{"key":"R26-5-20250124","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/00007890-199710150-00008","article-title":"Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age.","volume":"64","author":"Hjelmesaeth","year":"1997","journal-title":"Transplantation"},{"key":"R27-5-20250124","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00007890-198709000-00010","article-title":"The impact of cyclosporine and combination immunosuppression on the incidence of post-transplant diabetes in renal allograft recipients.","volume":"44","author":"Boudreaux","year":"1987","journal-title":"Transplantation"},{"key":"R28-5-20250124","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000166932","article-title":"Posttransplant diabetes in kidney transplant recipients.","volume":"5","author":"Friedman","year":"1985","journal-title":"Am J Nephrol"},{"key":"R29-5-20250124","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/00007890-199605270-00011","article-title":"Diabetes mellitus after renal transplantation: Characteristics, outcome and risk factors.","volume":"61","author":"Vesco","year":"1996","journal-title":"Transplantation"},{"key":"R30-5-20250124","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/BF03343761","article-title":"The metabolic effects of cyclosporin and tacrolimus.","volume":"23","author":"Marchetti","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"R31-5-20250124","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/00007890-199908150-00012","article-title":"Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation.","volume":"68","author":"Drachenberg","year":"1999","journal-title":"Transplantation"},{"key":"R32-5-20250124","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1034\/j.1600-6143.2003.00082.x","article-title":"Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients.","volume":"3","author":"Woodward","year":"2003","journal-title":"Am J Transplant"},{"key":"R33-5-20250124","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/01.TP.0000129095.51031.42","article-title":"Wu Y, et al on behalf of the LIS2T Study Group. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.","volume":"77","author":"Levy","year":"2004","journal-title":"Transplantation"},{"key":"R34-5-20250124","first-page":"268","article-title":"12-month follow-up data from a randomized, multicentre, prospective study of cyclosporine C2 monitoring versus tacrolimus in liver transplantation.","volume":"4","author":"Grazi","year":"2004","journal-title":"Am J Transplant"},{"issue":"Suppl","key":"R36-5-20250124","first-page":"SS3","article-title":"New-onset diabetes after transplantation: 2003 international consensus guidelines.","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"key":"R37-5-20250124","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in IDDM.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R38-5-20250124","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R39-5-20250124","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00007890-199908270-00015","article-title":"Poor outcome in patients with diabetes mellitus undergoing liver transplantation.","volume":"68","author":"Shields","year":"1999","journal-title":"Transplantation"},{"issue":"Suppl 5A","key":"R40-5-20250124","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/S0041-1345(01)02232-1","article-title":"Strategies for risk reduction and management of posttransplant diabetes mellitus.","volume":"33","author":"Marchetti","year":"2001","journal-title":"Transplant Proc"},{"key":"R41-5-20250124","first-page":"166","article-title":"Natural history, prognosis, and management of transplantation-induced diabetes mellitus.","volume":"28","author":"Benhamou","year":"2002","journal-title":"Diabetes Metab"},{"issue":"Suppl","key":"R42-5-20250124","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/j.healun.2004.03.007","article-title":"New-onset diabetes after transplantation.","volume":"23","author":"Marchetti","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"R43-5-20250124","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.24.1.154","article-title":"Hyperglycemic crises in patients with diabetes mellitus.","volume":"24","year":"2001","journal-title":"Diabetes Care"},{"issue":"Suppl 4","key":"R44-5-20250124","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1097\/01.CCM.0000115623.52021.C0","article-title":"Perioperative diabetic and hyperglycemic management issues.","volume":"32","author":"Coursin","year":"2004","journal-title":"Crit Care Med"},{"key":"R45-5-20250124","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0002-9343(01)00978-0","article-title":"The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.","volume":"111","author":"Huang","year":"2001","journal-title":"Am J Med"},{"key":"R46-5-20250124","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"R47-5-20250124","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.V1191735","article-title":"Explained and unexplained ischemic heart disease risk after renal transplantation.","volume":"11","author":"Kasiske","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R48-5-20250124","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00007890-200007270-00001","article-title":"Renal disease associated with hepatitis C infection after kidney and liver transplantation.","volume":"70","author":"Baid","year":"2000","journal-title":"Transplantation"},{"key":"R49-5-20250124","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0029-1212124","article-title":"Interferon-alpha improves glucose tolerance in diabetes and non-diabetic patients with HCV-induced liver disease.","volume":"107","author":"Konrad","year":"1999","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R50-5-20250124","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0168-8278(98)80214-6","article-title":"Steroid withdrawal is safe and beneficial in stable cyclosporin treated liver transplant patients.","volume":"28","author":"Gomez","year":"1998","journal-title":"J Hepatol"},{"key":"R51-5-20250124","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1432-2277.2000.tb01040.x","article-title":"Treatment of tacrolimus-related adverse effects by conversion to cyclosporin in liver transplant recipients.","volume":"13","author":"Emre","year":"2000","journal-title":"Transpl Int"},{"key":"R52-5-20250124","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1034\/j.1399-0012.2002.01054.x","article-title":"Bynon JS for the OLN-452 Study Group. Neoral rescue therapy in transplant patients with intolerance to tacrolimus.","volume":"16","author":"Abouljoud","year":"2002","journal-title":"Clin Transplant"},{"key":"R53-5-20250124","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0041-1345(03)00644-4","article-title":"Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus.","volume":"35","author":"Herrero","year":"2003","journal-title":"Transplant Proc"},{"key":"RU54-5-20250124","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1016\/S0041-1345(99)00663-6","article-title":"Diabetes mellitus and liver transplantation in adults.","volume":"31","author":"Marroni","year":"1999","journal-title":"Transplant Proc"},{"issue":"Suppl","key":"RU55-5-20250124","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1111\/j.1432-2277.1994.tb01302.x","article-title":"Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study.","volume":"7","author":"Ericzon","year":"1994","journal-title":"Transpl Int"},{"key":"RU56-5-20250124","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(02)11196-2","article-title":"Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomised controlled trial.","volume":"360","author":"OGrady","year":"2002","journal-title":"Lancet"},{"key":"RU57-5-20250124","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/s-2000-8127","article-title":"Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunosuppressive therapy by FK506tacrolimus.","volume":"108","author":"Lohmann","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"RU58-5-20250124","first-page":"1289","article-title":"Posttransplant diabetes mellitusa review.","volume":"58","author":"Jindal","year":"1994","journal-title":"Transplantation"},{"key":"RU59-5-20250124","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/S0041-1345(02)03018-X","article-title":"Cardiovascular risk factors in liver allograft recipients: Relationship with immunosuppressive therapy.","volume":"34","author":"Varo","year":"2002","journal-title":"Transplant Proc"},{"key":"RU60-5-20250124","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0041-1345(02)03020-8","article-title":"Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients.","volume":"34","author":"Rabkin","year":"2002","journal-title":"Transplant Proc"},{"key":"RU61-5-20250124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/lt.500030101","article-title":"Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506).","volume":"3","author":"Canzanello","year":"1997","journal-title":"Liver Transpl Surg"},{"key":"RU62-5-20250124","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0041-1345(98)00295-4","article-title":"Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation.","volume":"30","author":"Cai","year":"1998","journal-title":"Transplant Proc"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.20439","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200506000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T16:01:25Z","timestamp":1737734485000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200506000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.20439","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}